
Opinion|Videos|February 27, 2026
Key Communication Strategies in EGFR+ NSCLC Management
Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, discuss communication strategies between specialists and patients in EGFR-mutated NSCLC management.
Advertisement
Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, explore communication approaches that facilitate shared decision-making in EGFR-mutated non–small cell lung cancer. Florez emphasizes tailoring discussions to patient health literacy and cultural context to ensure treatment understanding and engagement. McDonald highlights practical techniques for reinforcing education during follow-up visits and maintaining clear communication across the care team.
Advertisement
Related to this article

The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.

The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.

The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.

By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.

TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.

An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
The OncFive: Top Oncology Articles for the Week of 9/27/2026
3
FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC
4
AUA Releases Guideline Amendment for NMIBC
5

